Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial ...

But an association with improved overall survival failed to reach statistical significance ...

Prostate cancer has been of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

In a new study published in the journal Nature Genetics, Haolong Li, PhD, a researcher at Fred Hutch Cancer Center, and colleagues developed a way to monitor androgen receptor levels inside living ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

Adding metastasis-directed therapy (MDT) to standard of care was tied to improvements in several survival endpoints in oligometastatic prostate cancer, a recent analysis suggests.